NYSE

Pharma

With an oversubscribed trading debut now in the books, Veradermics is well coiffed to tap into the growing opportunity for pattern hair loss drugs.

Fraiser Kansteiner Feb 5, 2026 10:01am

Sep 29, 2025 10:05am